The global multiple myeloma therapeutics market was valued at USD 7.5 billion in 2015 and is expected to reach a value of USD 37.5 billion by 2024. Key factors driving the market expansion include constant introduction of newer and effective therapeutic options and high adoption rates of the same.
This space is expected to gain momentum with the addition of novel drugs to the current therapeutics array with monoclonal antibodies and Histone Deacetylase (HDAC) inhibitors. Due to failed outcomes of the currently available medication, there is a high demand for effective treatment strategies to offset therapeutic dissatis faction and increase life expectancies of patients; which in turn is expected to boost the research and development of improved therapies for multiple myeloma.
Growing prevalence of the disease along with the surging elderly population is the prime factor expected to drive the growth significantly during the forecast period. Complications involved in treating geriatric patients are driving the demand for supportive treatments such as restoration procedures involving transfusion of blood components and point of care technologies.
The U.S, followed by Europe, has been dominating the market owing to the presence of major players in these regions, faster approval rates, and favorable healthcare policies. Higher prevalence of multiple myeloma in the developed economies is a pivotal determinant driving the growth of the Europe market.
The space consists of a few major players including Celgene Corporation, Janssen Biotech, Inc., Bristol-Myers Squibb Company, and Novartis AG. A large revenue share is captured by Celgene Corporation with its high-performing drug, Revlimid. The drug currently dominates the market with more than 50% share of the total multiple myeloma therapeutics market.
Multiple Myeloma Therapeutics Market, USD Million, 2014 - 2024
To request a sample copy or view summary of this report, click the link below:
Further Key Findings from the Study Suggest:
Grand View Research has segmented the multiple myeloma therapeutics market by product and region:
Multiple Myeloma Therapeutics Type Outlook (Revenue, USD Billion, 2014 - 2024)
Multiple Myeloma Therapeutics Regional Outlook (Revenue, USD Billion, 2014 - 2024)
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
The global laboratory informatics market size is expected to reach USD 4.72 billion by 2027, expanding at a CAGR of 6.6% from 2020 to 2027, according to a recent study conducted by Grand View Research, ..
The global vein illuminator market size is expected to reach USD 793.8 million by 2027, registering revenue based CAGR of 30.6% over the forecast period, according to a new report by Grand View Research, ..
The global surgical microscopes market size is estimated to reach USD 2.1 billion by 2027 and is expected to register a CAGR of 10.9% over the forecast period, according to a new report by Grand View ..
この項目では、 1964年 に 東京都 で開催された夏季オリンピックについて説明しています。 2021年 に東京都で開催される予定の夏季オリンピックについては「 2020年東京オリンピック 」をご覧ください。 1940年 に 東京市 で開催される予定であった夏季オリンピックについては「 1940年東京オリンピック 」をご覧ください。 その他については「 東京オリンピック (曖昧さ回避) 」をご覧ください。 ..
https://www.uottawa.ca/undergraduate-admissions/sites/www.uottawa.ca.undergraduate-admissions/files/free-v-bucks-generator-glitch.pdf https://admission.rice.edu/sites/g/files/bxs676/f/webform/test_form_files/free-v-bucks-generator-glitch.pdf ..